Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

9.7%

7 terminated/withdrawn out of 72 trials

Success Rate

87.9%

+1.4% vs industry average

Late-Stage Pipeline

35%

25 trials in Phase 3/4

Results Transparency

76%

39 of 51 completed trials have results

Key Signals

7 recruiting39 with results

Enrollment Performance

Analytics

Phase 2
23(35.9%)
Phase 3
19(29.7%)
Phase 1
15(23.4%)
Phase 4
6(9.4%)
Early Phase 1
1(1.6%)
64Total
Phase 2(23)
Phase 3(19)
Phase 1(15)
Phase 4(6)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (72)

Showing 20 of 72 trials
NCT05518578Phase 2Recruiting

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

Role: lead

NCT05066672Phase 2Completed

Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

Role: collaborator

NCT06185985Phase 4Completed

Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms

Role: lead

NCT07226661Phase 2Recruiting

Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

Role: lead

NCT04781140Phase 4Recruiting

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

Role: lead

NCT04050293Phase 4Terminated

Therapy for Migraine Prevention in Children 6-11 Years of Age

Role: lead

NCT05655520Phase 3Terminated

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

Role: lead

NCT00626236Phase 2Completed

Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems

Role: lead

NCT01246765Recruiting

National Pregnancy Registry for Psychiatric Medications

Role: collaborator

NCT07219927Recruiting

Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:

Role: lead

NCT06235905Phase 2Completed

Open-Label of SPN-820 in Adults With Major Depressive Disorder

Role: collaborator

NCT02477618Phase 3Completed

A Study With SAGE-547 for Super-Refractory Status Epilepticus

Role: lead

NCT02942004Phase 3Completed

A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)

Role: lead

NCT07141329Phase 2Recruiting

SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures

Role: lead

NCT03771586Phase 1Completed

A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

Role: lead

NCT05049343Phase 1Completed

Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants

Role: lead

NCT03787758Phase 1Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B

Role: lead

NCT03770780Phase 1Completed

A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

Role: lead

NCT03844906Phase 1Completed

A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects

Role: lead

NCT02052739Phase 1Completed

Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

Role: lead